Search results for "survival analysi"

showing 10 items of 752 documents

Prognostic value of hyperattenuating middle cerebral artery sign at CT in cerebral infarction

2004

To assess the prognostic value of hyperattenuating middle cerebral artery sign at CT in acute cerebral infarction.Ninety-two patients with acute cerebral infarction in the sylvian area were retrospectively reviewed. All patients underwent unenhanced CT 12-24 hours after the onset of symptoms and follow-up CT within 48-72 hours. Initial CT scans were evaluated by consensus by three radiologists to confirm or exclude the presence of hyperattenuating middle cerebral artery sign. History, cardiovascular risk factors and neurological impairment at discharge (mean 25 days) were recorded for each patient. The degree of disability was graded 0 (no disability) to 6 (death). Patients were divided int…

MaleMiddle Cerebral ArteryTime FactorsLogistic ModelTime FactorPrognosiHypercholesterolemiaPredictive Value of TestSex FactorFollow-Up StudieDiabetes ComplicationsSex FactorsPredictive Value of TestsRisk FactorsRetrospective StudieDiabetes ComplicationAtrial FibrillationHumansDisabled PersonsAge FactorRetrospective StudiesAgedRisk FactorAge FactorsCerebral InfarctionMiddle AgedPrognosisSurvival AnalysisLogistic ModelsAcute DiseaseHypertensionDisabled PersonFemaleSurvival AnalysiTomography X-Ray ComputedFollow-Up StudiesHuman
researchProduct

Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil–based chem…

2014

Background & Aims Patients with colorectal tumors with microsatellite instability (MSI) have better prognoses than patients with tumors without MSI, but have a poor response to 5-fluorouracil–based chemotherapy. A dominant-negative form of heat shock protein (HSP)110 (HSP110DE9) expressed by cancer cells with MSI, via exon skipping caused by somatic deletions in the T 17 intron repeat, sensitizes the cells to 5-fluorouracil and oxaliplatin. We investigated whether HSP110 T 17 could be used to identify patients with colorectal cancer who would benefit from adjuvant chemotherapy with 5-fluorouracil and oxaliplatin. Methods We characterized the interaction between HSP110 and HSP110DE9 using su…

MaleModels MolecularOrganoplatinum CompoundsColorectal cancermedicine.medical_treatment[SDV]Life Sciences [q-bio]Leucovorin0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsHSP110 Heat-Shock ProteinsComputingMilieux_MISCELLANEOUSColectomySequence Deletion0303 health sciencesGastroenterologyPrimary tumor3. Good healthOxaliplatinTreatment OutcomeFluorouracilChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleMicrosatellite InstabilityFluorouracilColorectal Neoplasmsmedicine.drugBlotting WesternAntineoplastic AgentsBiology03 medical and health sciencesCell Line TumormedicineBiomarkers TumorHumans030304 developmental biologyAgedRetrospective StudiesChemotherapyHepatologyBase SequenceMicrosatellite instabilityCancerSurface Plasmon Resonancemedicine.diseaseMolecular biologySurvival AnalysisIntronsOxaliplatinCancer cellCancer researchFollow-Up StudiesGastroenterology
researchProduct

Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study

2013

Population-based information on the survival of patients with myeloid malignancies is rare mainly because some entities were not recognized as malignant until the publication of the third revision of the International Classification of Diseases for Oncology and World Health Organization classification in 2000. In this study we report the survival of patients with myeloid malignancies, classified by updated criteria, in Europe. We analyzed 58,800 cases incident between 1995 to 2002 in 48 population-based cancer registries from 20 European countries, classified into HAEMACARE myeloid malignancy groupings. The period approach was used to estimate 5-year relative survival in 2000-2002. The rela…

MaleMyeloidMyeloproliferative disorders -- DiagnosisMyelodysplastic–myeloproliferative diseaseshemic and lymphatic diseasesMyelodysplastic Syndromes/embryology/mortalityRegistriesCàncerCancerAged 80 and overMielomeseducation.field_of_studyRelative survivalMyeloid leukemiaArticlesHematologyMiddle AgedEuropemedicine.anatomical_structureMyelodysplastic-Myeloproliferative Diseases/epidemiology/mortalityAplastic anemia -- TreatmentFemaleAdultmedicine.medical_specialtyAdolescentPopulationMyelodysplastic syndromesmyeloid malignancies; survivalmyeloid malignanciesBone marrow -- TumorssurvivalNOEurope/epidemiologyYoung AdultInternal medicinemedicineHumanseducationSurvival analysisddc:613AgedMedul·la òssia -- TumorsEssential thrombocythemiabusiness.industryMyelodysplastic syndromesmedicine.diseaseThrombocytopeniaMyelodysplastic-Myeloproliferative DiseasesSurvival AnalysisMyelodysplastic SyndromesImmunologyMyélomesbusiness
researchProduct

The impact of home palliative care on symptoms in advanced cancer patients

2000

Physical symptoms, which are highly prevalent in patients with cancer, have a major impact on many aspects of quality of life, and the best possible quality of life is the principal aim of palliative care. Few studies have reported the impact of home care on pain and symptoms among cancer patients living at home. The aim of this study was to evaluate the impact of home palliative care given by an experienced team on symptoms in advanced cancer patients. A consecutive series of 373 patients who were referred to a home palliative care program in the period 1993-1995 were prospectively evaluated. Patients were enrolled for the presence of different symptoms (pain, nausea and vomiting, dry mout…

MaleNarcoticsPediatricsmedicine.medical_specialtyWeaknessPalliative careConstipationEpidemiologyNauseaPain medicinePainHome careEatingQuality of life (healthcare)NeoplasmsmedicineHumansSymptomatic treatmentAgedRetrospective Studiesbusiness.industryHome Care ServicesSurvival AnalysisAdvanced cancer patientDysphagiaOncologyQuality of LifePalliative careVomitingPhysical therapyFemalemedicine.symptombusinessSupportive Care in Cancer
researchProduct

The 15-Country Collaborative Study of Cancer Risk among Radiation Workers in the Nuclear Industry: Estimates of Radiation-Related Cancer Risks

2007

International audience; A 15-Country collaborative cohort study was conducted to provide direct estimates of cancer risk following protracted low doses of ionizing radiation. Analyses included 407,391 nuclear industry workers monitored individually for external radiation and 5.2 million person-years of follow-up. A significant association was seen between radiation dose and all-cause mortality [excess relative risk (ERR) 0.42 per Sv, 90% CI 0.07, 0.79; 18,993 deaths]. This was mainly attributable to a dose-related increase in all cancer mortality (ERR/Sv 0.97, 90% CI 0.28, 1.77; 5233 deaths). Among 31 specific types of malignancies studied, a significant association was found for lung cance…

MaleNeoplasms Radiation-InducedInternational Cooperation[SDV]Life Sciences [q-bio]Radiation inducedradiation exposurenuclear industrycancer riskWhole-Body Counting030218 nuclear medicine & medical imagingCohort Studiescause of death0302 clinical medicineNuclear industryNuclear ReactorsRisk FactorsNeoplasmscancer mortalityMedicineRadiation injuryRadiationindustryadultarticleleukemiarisk assessmentmethodologycohort analysis3. Good healthmultiple myelomaOccupational DiseasesSurvival Ratefemalepriority journalrisk factorstatistics030220 oncology & carcinogenesisemploymentFemaleionizing radiationradiation doseCohort studyradiation injuryAdultEmploymentBiophysicsRadiation DosageRisk Assessmentsurvival03 medical and health sciencessocioeconomicsOccupational ExposureIndustryfollow upHumansRadiology Nuclear Medicine and imaginghumanRisk factorindustrial workerWhole body countingbusiness.industryNicotiana tabacumCancermedicine.diseasemortalitySurvival Analysislung cancerwhole body countingconfidence intervalRadiation-Inducedoccupational diseasenuclear reactorbusinessNuclear medicineCancer riskDemography
researchProduct

Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuxim…

2012

Purpose To evaluate the addition of cetuximab to neoadjuvant chemotherapy before chemoradiotherapy in high-risk rectal cancer. Patients and Methods Patients with operable magnetic resonance imaging–defined high-risk rectal cancer received four cycles of capecitabine/oxaliplatin (CAPOX) followed by capecitabine chemoradiotherapy, surgery, and adjuvant CAPOX (four cycles) or the same regimen plus weekly cetuximab (CAPOX+C). The primary end point was complete response (CR; pathologic CR or, in patients not undergoing surgery, radiologic CR) in patients with KRAS/BRAF wild-type tumors. Secondary end points were radiologic response (RR), progression-free survival (PFS), overall survival (OS), an…

MaleOncologyCancer ResearchOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentCetuximabKaplan-Meier Estimatemedicine.disease_causeDeoxycytidineGastroenterologyIntestinal mucosaAntineoplastic Combined Chemotherapy ProtocolsIntestinal MucosaColectomyNeoadjuvant therapyCetuximabAntibodies MonoclonalMiddle AgedCombined Modality TherapyNeoadjuvant TherapyOxaliplatinTreatment OutcomeOncologyFemaleFluorouracilKRASmedicine.drugAdultmedicine.medical_specialtyAdenocarcinomaAntibodies Monoclonal HumanizedRisk AssessmentDisease-Free SurvivalCapecitabineInternal medicinePreoperative CaremedicineHumansNeoplasm InvasivenessneoplasmsCapecitabineAgedNeoplasm StagingAnalysis of VarianceRectal Neoplasmsbusiness.industryChemoradiotherapy Adjuvantmedicine.diseaseSurvival AnalysisUnited Kingdomdigestive system diseasesOxaliplatinLogistic ModelsRadiotherapy AdjuvantbusinessChemoradiotherapyFollow-Up StudiesJournal of Clinical Oncology
researchProduct

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

2001

Researchers worldwide with information about the Kirsten ras (Ki-ras) tumour genotype and outcome of patients with colorectal cancer were invited to provide that data in a schematized format for inclusion in a collaborative database called RASCAL (The Kirsten ras in-colorectal-cancer collaborative group). Our results from 2721 such patients have been presented previously and for the first time in any common cancer, showed conclusively that different gene mutations have different impacts on outcome, even when the mutations occur at the same site on the genome. To explore the effect of Ki-ras mutations at different stages of colorectal cancer, more patients were recruited to the database, whi…

MaleOncologyCancer ResearchPathologyMultivariate analysisDatabases FactualSettore MED/06 - Oncologia MedicaColorectal cancerGene mutationmedicine.disease_cause0302 clinical medicineGenotypeColorectal cancer Ki-ras mutationRegistriesAged 80 and over0303 health sciencesMutationValineMiddle Aged3. Good healthKRAS Mutation Analysismedicine.anatomical_structureOncologyPresented by the Kirsten ras in-colorectal-cancer collaborative group030220 oncology & carcinogenesisFemaleColorectal NeoplasmsAdultmedicine.medical_specialtyAdolescentGenotypeoverall survivalMutation MissenseRectumcolorectal cancerDisease-Free Survival03 medical and health sciencesInternal medicinemedicineHumansPoint MutationK-rasCodoncolorectal cancer; K-ras; prognosis; overall survivalAgedNeoplasm StagingProportional Hazards Models030304 developmental biologybusiness.industryCancermedicine.diseaseSurvival AnalysisGenes rasMultivariate Analysisprognosisbusiness
researchProduct

DNA aneuploidy and high proliferative activity but not K-ras-2 mutations as independent predictors of clinical outcome in operable gastric carcinoma:…

2001

BACKGROUND The prognostic value of DNA ploidy, S-phase fraction (SPF) and K-ras-2 mutations in gastric carcinoma (GC) has not yet been clearly defined. The aim of this study was to clarify the association between biomolecular variables, tumor characteristics, and clinical outcome in GC patients. METHODS Resected specimens from a consecutive series of 69 patients with GC who underwent potentially curative surgery were studied prospectively. DNA ploidy and SPF were assessed by flow cytometry on multiple frozen tumor samples, whereas K-ras-2 mutations were detected by polymerase chain reaction followed by single-strand conformation polymorphism. All the patients involved in this study were fol…

MaleOncologyCancer ResearchPathologyStagingSettore MED/06 - Oncologia MedicaAneuploidyPolymerase Chain ReactionS Phaselaw.inventionRisk FactorslawProspective StudiesStage (cooking)Prospective cohort studyK-ras-2Polymorphism Single-Stranded ConformationalPolymerase chain reactionUnivariate analysisDNA NeoplasmMiddle AgedFlow CytometryPrognosisOncologyFemaleAdultmedicine.medical_specialtyPrognosiGastrectomyPredictive Value of TestsStomach NeoplasmsInternal medicineBiomarkers TumorCarcinomamedicineHumansNeoplasm InvasivenessSurvival analysisAgedNeoplasm Stagingbusiness.industryCarcinomaGastric carcinomaCancerAneuploidymedicine.diseaseSurvival AnalysisGenes rasDNA ploidyNeoplasm Recurrence LocalbusinessS-phase fraction
researchProduct

High expression of GLI1 is associated with better survival in advanced SCLC

2020

Aim Aberrant Sonic hedgehog (Shh) pathway signaling has been described in small cell lung cancer (SCLC), as well discrepancies, when analyzing expression of pathway components in SCLC cell lines vs tumor biopsies. Shh key component GLI1 was evaluated in advanced SCLC and data correlated with patient survival. Materials and methods GLI1 expression was analyzed by quantitative real-time polymerase chain reaction in pre-treatment fresh frozen tumor biopsies of 12 advanced SCLC patients and mRNA level of GLI1 was compared in short-term vs long-term survivor's samples (stratified by median survival, independent samples t-test). Results Expression of GLI1 mRNA was significantly higher in long-ter…

MaleOncologyCancer Researchmedicine.medical_specialtyLung NeoplasmsBiopsyZinc Finger Protein GLI1law.invention03 medical and health sciences0302 clinical medicineText mininglawGLI1Internal medicineHumansMedicineHedgehog ProteinsRNA MessengerSonic hedgehogPolymerase chain reactionAgedNeoplasm StagingMessenger RNAbiologybusiness.industryMiddle AgedSmall Cell Lung CarcinomaSurvival AnalysishumanitiesOncologyMrna levelCell culture030220 oncology & carcinogenesisbiology.proteinFresh frozenFemalebusinessExperimental Oncology
researchProduct

Improvement in survival of metastatic colorectal cancer: Are the benefits of clinical trials reproduced in population-based studies?

2012

To describe trends in survival of non-resectable metastatic colorectal cancer (MCRC) over a 34-year period in a French population-based registry taking into account major advances in medical therapy.3804 patients with non-resectable metastatic colorectal cancer diagnosed between 1976 and 2009 were included. Three periods (1976-96, 1997-2004 and 2005-09) were considered.The proportion of patients receiving chemotherapy dramatically increased from 19% to 57% between the first two periods, then increased steadily thereafter reaching 59% during the last period (p0.001). Median relative survival increased from 5.9 months during the 1976-96 period to 10.2 months during the 1997-2004 period but, d…

MaleOncologyCancer Researchmedicine.medical_specialtyTime FactorsColorectal cancermedicine.medical_treatmentPopulationAntineoplastic AgentsPopulation basedHealth Services AccessibilityInternal medicinemedicineHumansMolecular Targeted TherapyRegistriesHealthcare DisparitieseducationAgedClinical Trials as TopicChemotherapyeducation.field_of_studyEvidence-Based MedicineMedical treatmentbusiness.industryPatient SelectionPalliative CareAge FactorsTreatment optionsMiddle Agedmedicine.diseaseSurvival AnalysisSurvival RateClinical trialTreatment OutcomeOncologyFemaleFranceDiffusion of InnovationColorectal NeoplasmsbusinessMedical therapyEuropean Journal of Cancer
researchProduct